KANJINTITM was approved by the EMA on May 16, 2018 and by the FDA on June 13, 2019 for the same indications approved for Herceptin including human epidermal growth factor receptor-2 (HER2)-overexpressing early breast cancer, metastatic breast cancer, and metastatic gastric cancer. This evidence concerns the gene ERBB2 and breast carcinoma.